Navigation Links
Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission
Date:5/21/2008

.

Worsening congestive heart failure (CHF) has been observed with TNF-blocking agents, including HUMIRA, and new onset CHF has been reported with TNF-blocking agents. Treatment with HUMIRA may result in the formation of autoantibodies and rarely, in development of a lupus-like syndrome.

In the placebo-controlled clinical studies of adult patients with rheumatoid arthritis, the most frequent adverse reactions vs. placebo were injection site reactions (20 percent vs. 14 percent), upper respiratory infection (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 percent vs. 8 percent), rash (12 percent vs. 6 percent) and sinusitis (11 percent vs. 9 percent). Discontinuations due to adverse events were 7 percent for HUMIRA and 4 percent for placebo.

In HUMIRA clinical trials for ankylosing spondylitis, psoriatic arthritis, Crohn's disease and plaque psoriasis, the safety profile for adult patients treated with HUMIRA was similar to the safety profile seen in adult patients with rheumatoid arthritis. In the placebo-controlled clinical trials in plaque psoriasis, the incidence of arthralgia was 3 percent in HUMIRA-treated patients versus 1 percent in controls.

In general, adverse reactions in pediatric patients were similar in frequency and type to those seen in adult patients. Severe adverse reactions reported in the clinical trial of juvenile idiopathic arthritis (JIA) included neutropenia, streptococcal pharyngitis, increased aminotransferases, herpes zoster, myositis, metrorrhagia and appendicitis. Serious infections were observed in 4 percent of patients within approximately 2 years of initiation of treatment with HUMIRA and included cases of herpes simplex, pneumonia, urinary tract infection, pharyngitis, and herpes zoster. Safety of HUMIRA in pediatric patients for uses other than JIA has not been established.

As with any treatment program, the benefits and risks of HUMIRA should be carefully co
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
2. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
3. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
4. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
5. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
6. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
7. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
9. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
10. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
11. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)...   , July 2, 2015 BGI ... Hong Kong has been accredited ... Kong facility is the first clinical next-generation-sequencing laboratory to ... , meeting the highest standard in clinical laboratory practices. Complementary ... 11 compliant laboratory process, and multiple ISO certifications, the ...
(Date:7/1/2015)... The Coalition of State Rheumatology Organizations ... professional rheumatology societies, today released the findings of ... of biosimilars and the potential impact of these ... are medicines that are highly similar, but not ... from generic medications in that it is impossible ...
(Date:7/1/2015)... -- Eli Lilly and Company (NYSE: LLY ) will ... on Thursday, July 23, 2015. Lilly will also conduct a ... media to further detail the company,s financial performance. ... media and the general public can access a live webcast ... posted on Lilly,s website at www.lilly.com . A replay ...
Breaking Medicine Technology:BGI Receives Accreditation from the College of American Pathologists (CAP) 2Survey Of Rheumatologists Nationwide Regarding Biosimilars Highlights Need For More Robust FDA Standards 2Lilly Confirms Date and Conference Call for Second-Quarter 2015 Financial Results Announcement 2
... Mylan Inc. (Nasdaq: MYL ) today ... entered into a settlement agreement with Warner Chilcott resolving ... as Norethindrone and Ethinyl Estradiol Tablets USP (Chewable), 0.4 ... mg (28-Day Regimen). This medication is an oral contraceptive. ...
... NEW YORK, Oct. 19, 2011 Reportlinker.com announces ... in its catalogue: Syncria ... 2020 http://www.reportlinker.com/p0657174/Syncria-Type-2-Diabetes-–-Analysis-and-Forecasts-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Forecasts to 2020 Summary ...
Cached Medicine Technology:Mylan Announces Femcon® Fe Settlement Agreement 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 2Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 3Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 4Syncria (Type 2 Diabetes) - Analysis and Forecasts to 2020 5
(Date:7/2/2015)... ... ... After conducting a nationwide executive search led by healthcare leadership ... has hired Robert Trenschel, DO, as chief executive officer. A veteran physician executive with ... new duties at Yuma Regional Medical Center on July 13. , “Dr. Trenschel brings ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... is announcing with their launch an intention to partner with companies that share ... on the planet. Their innovative water soluble, Cannabidiol (CBD) formulations, combined with Ayurvedic ...
(Date:7/2/2015)... ... July 02, 2015 , ... Today, East Liverpool City ... Surgical Center at East Liverpool City Hospital (ELCH). Pam is currently the Chief Nursing ... the director of surgery. Pam holds a master’s degree in health care administration as ...
(Date:7/2/2015)... ... ... As part of the celebration of its 70th anniversary, the Thantakit International ... all around the world for their continuous patronage of the world-class services of their ... (indeed, Thantakit is one of the foremost places for dental tourism in Thailand) or ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... their products, services, channels and business models. To help manage the increasing demand ... addition of Mark Benkendorf as SVP of Strategic Engagements. , Benkendorf is a ...
Breaking Medicine News(10 mins):Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 2Health News:Yuma Regional Medical Center Hires New Chief Executive Officer 3Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 2Health News:New Water Soluble CBD Provides Manufacturers & Distributors a More Effective, Safe, & Cost Efficient Alternative to Traditional CBD Oil 3Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 2Health News:East Liverpool City Hospital Announces New Surgical Center Leadership 3Health News:Thailand's Longest Established International Dental Center Celebrates Its 70th Anniversary with Promos Galore 2Health News:Business Builder Mark Benkendorf Joins Innovation Firm Maddock Douglas 2
... study published in,the November 2008 issue of the American ... dense breakfast have improved diet,quality, and may have a ... that those who enjoy a less energy dense morning ... minerals and lower in,saturated fat and cholesterol compared to ...
... U-M Health Minute: Today,s top health issues and medical research, ... diabetes for nine years, and he knows the importance of ... the feet., "Knowing some of the warning signs of ... things immediately I knew would prevent larger,issues, I see the ...
... gains with shorter intervention programs aren,t sustained , , ... survivors can significantly reduce their risk of non-fatal ... prevention program, according to an Italian study that ... of post-heart attack rehabilitation, half the patients were ...
... Grand Opening Celebration of Ocean,Blue Plastic Surgery is ... p.m. Ocean Blue Plastic Surgery is located on ... Guests are invited to enjoy the,Carlos Miele fashion ... hors d,oeuvres and sipping cocktails provided by Select ...
... NEW YORK, Nov. 11 WebMD Health Corp. (Nasdaq:,WBMD) ... Heroes awards,featured in the November/December issue of WebMD the ... Americans who face health,issues with the vision and drive ... Starts Revolutionary Movement to Help End Cancer, Laura ...
... Health Book Summaries, the free,book summary service ... achieved,the 60,000 subscriber milestone. The service delivers free, ... Belief" by Dr. Bruce,Lipton and "Appetite for Profit" ... , Launched in mid-2008, the Health Book ...
Cached Medicine News:Health News:Breakfast Improves Overall Diet Quality and May Help with Weight Management 2Health News:Breakfast Improves Overall Diet Quality and May Help with Weight Management 3Health News:Foot Problems Common Among People With Diabetes 2Health News:Foot Problems Common Among People With Diabetes 3Health News:Long-Term Help Regimen Cut Heart Attack Recurrence 2Health News:Ocean Blue Plastic Surgery to Open This Month on Brickell Avenue 2Health News:WebMD Announces 2008 Health Heroes 2Health News:WebMD Announces 2008 Health Heroes 3Health News:Health Book Summaries Subscriber Base Grows to 60,000 Readers as Health Consumers Applaud Free Format 2
... Digital Flexible Ureteroscope (DUR-D) incorporates many ... proven durable, market leading DUR® series ... first device utilizing Gyrus ACMIs proprietary, ... Metal Oxide Semi-Conductor (CMOS) distal sensor ...
... is the first one-step 20 minutes rapid test ... 2 produced by Enterohemorrhagic Escherichia coli in human ... enrichment of fecal specimens and detects all Toxigenic ... separate result for Toxin 1 and 2 is ...
Inquire...
... elegant and sophisticated woman, the ... ophthalmic and sunwear styles. Frames ... of shapes and colors, designed ... and complexions. Many styles feature ...
Medicine Products: